Exercise and Time of Day in Type 2 Diabetes

Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Oct 26, 2021

Keywords

ClinConnect Summary

This clinical trial, titled "Exercise and Time of Day in Type 2 Diabetes," is exploring how a program called Noom can help adults with type 2 diabetes improve their diet and exercise habits. The researchers believe that using Noom alongside an exercise routine may help participants stick to healthier eating, leading to more weight loss and better overall health, particularly in terms of controlling blood sugar and blood pressure.

To join the study, participants need to be between 30 and 70 years old, have a body mass index (BMI) between 28 and 45, and have a confirmed diagnosis of type 2 diabetes. However, some individuals, such as those with severe obesity (BMI over 46), those who smoke, or those with certain medical conditions, may not be eligible. Participants will engage in an exercise program and receive guidance on diet, and they can expect to learn more about how their lifestyle changes can positively impact their health. This study is currently recruiting participants, and it's a great opportunity for those looking to make lasting changes in their health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female \>30 and \<70 years old.
• • Has a body mass index \>28 and \<45 kg/m2.
• • Previously diagnosed with T2DM.
• • Subjects currently taking medications that affect heart rate and rhythm (i.e. Ca++ channel blockers, nitrates, alpha- or beta-blockers).
• Exclusion Criteria:
• • Morbidly obese patients (BMI \>46 kg/m2) and overweight/lean patients (BMI \<27 kg/m2)
• • Evidence of type 1 diabetes and diabetics requiring insulin therapy
• • Subjects who have not been weight stable (\>2 kg weight change in past 3 months)
• • Subjects who have been recently active (\>30 min of moderate/high intensity exercise, 2 times/week).
• • Subjects who are smokers or who have quit smoking \<1 years ago
• • Subjects with abnormal estimated glomerular filtration rate (eGFR).
• • Hypertriglyceridemic (\>400 mg/dl) and hypercholesterolemic (\>260 mg/dl) subjects
• • Hypertensive (\>160/100 mmHg)
• • Subjects with a history of significant metabolic, cardiac, congestive heart failure, cerebrovascular, hematological, pulmonary, gastrointestinal, liver, renal, or endocrine disease or cancer that in the investigator's opinion would interfere with or alter the outcome measures or impact subject safety.
• • Pregnant (as evidenced by positive urine pregnancy test) or nursing women
• • Subjects with contraindications to participation in an exercise training program
• • Currently taking active weight suppression medication (e.g. phentermine,orlistat, lorcaserin, naltrexone-bupropion in combination, liraglutide, benzphetamine, diethylpropion, phendimetrazine)
• • Known hypersensitivity to perflutren (contained in Definity)